LC
CALA

Lindbrook Capital’s Calithera Biosciences, Inc CALA Stock Holding History

Lindbrook Capital’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-500
Closed -$1K – 3027
2022
Q2 		$1K Buy
+500
New +$2.32K ﹤0.01% 2451
2020
Q3 		– Sell
-61
Closed -$6K – 1887
2020
Q2 		$6K Buy
+61
New +$7.25K ﹤0.01% 1058

Other funds holding CALA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lindbrook Capital's CALA Position: Q3 2022 in Review

Lindbrook Capital sold out of Calithera Biosciences, Inc (CALA) in Q3 2022, closing a stake of 500 shares — an estimated $1K sold.

Lindbrook Capital first reported a position in CALA in Q2 2020 and held it in 2 quarters. The position peaked at $6K in Q2 2020. 22 funds tracked by Wall St. Rank hold CALA as of Q3 2022.

  • Lindbrook Capital reported no remaining Calithera Biosciences, Inc position as of Q3 2022 after selling out during the quarter.
  • Lindbrook Capital sold 500 Calithera Biosciences, Inc shares in Q3 2022, an estimated $1K.
  • Lindbrook Capital first reported a position in Calithera Biosciences, Inc in Q2 2020 and held it in 2 quarters.
  • Lindbrook Capital's Calithera Biosciences, Inc position peaked at $6K in Q2 2020.
  • 22 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q3 2022.

Based on Lindbrook Capital's 13F filing for Q3 2022, filed 10 Nov 2022.